New York, NYNCT05691010Now EnrollingIRB Ready

Endometrial Cancer Clinical Trial in New York, NY

Access cutting-edge endometrial cancer treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access endometrial cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related endometrial cancer treatment provided free

Apply for This New York Location

Check if you qualify for this endometrial cancer clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Endometrial Cancer Study in New York

The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Patients must have newly diagnosed endometrial carcinoma. The following histologic subtypes are eligible for inclusion: endometrioid, serous, clear cell, dedifferentiated/undifferentiated, mixed epithelial, adenocarcinoma not otherwise specified, and carcinosarcoma.
Surgery must have included a hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node surgical assessment (sentinel lymph node mapping and/or sampling). Para-aortic lymph node surgical assessment is optional.
Patients must have FIGO (2009) stage IIIA or IIIC1 disease (as determined by surgical staging).
Patients must consent to testing with MSK-IMPACT part A and are encouraged to consent to both parts A and C.
Age ≥ 18 years.
Patients must have an Karnofsky Performance Status (KPS) ≥ 70 (or ECOG 0 or 1).
Neurologic function: Neuropathy (sensory and motor) grade ≤ 1.
No residual gross disease after surgery.
No prior radiation therapy or chemotherapy for treatment of endometrial cancer.
No active infection requiring antibiotics, except for uncomplicated urinary tract infection.
Patients must have adequate organ function, defined by the following laboratory results prior to first study treatment:
Absolute neutrophil count (ANC) ≥ 1500/mcL
Platelet count ≥ 100,000/mcL
AST/ALT ≤ 3X upper limit of normal (ULN)
Total bilirubin ≤ 1.5X ULN. Patients with known Gilbert's disease and a total bilirubin ≤ 3X ULN may be enrolled.
Creatinine ≤ 1.5X ULN
Entry into study is limited to no more than 12 weeks from the date of surgery.
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Patients of childbearing age will by definition have undergone hysterectomy and bilateral oophorectomy prior to study enrollment.
Participants must agree not to breastfeed during the study or for 150 days after the last dose of study treatment.

Exclusion Criteria

Patients whose endometrial cancers harbor known pathogenic POLE mutations
Patients whose endometrial cancers are mismatch repair deficient, as determined by immunohistochemical staining for MLH1, PMS2, MSH2, and MSH6 and/or MSI-H
Active inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. This includes but is not limited to: uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, chronic obstructive pulmonary disease, uncontrolled major seizure disorder, unstable spinal cord compression, and superior vena cava syndrome.
Patients unfit for pelvic radiation therapy due to the following:
Has had radiation therapy encompassing \>20% of the bone marrow within 2 weeks, or any radiation therapy within 1 week prior to day 1 of protocol therapy
Patients with a history of pelvic radiation.
Patients with a history or current diagnosis of a vesicovaginal, enterovaginal, or colovaginal fistula.
Any hematological abnormality or disorder that would be a contraindication to radiation per the treating physician.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT05691010) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Endometrial Cancer Treatment Options in New York, NY

If you're searching for endometrial cancer treatment options in New York, NY, this clinical trial (NCT05691010) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced endometrial cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all endometrial cancer clinical trials near you to find additional studies recruiting in your area.

More Endometrial Cancer Trials in New York, NY

See all endometrial cancer clinical trials recruiting in New York — not just this study.

Browse Endometrial Cancer Trials in New York →

Browse More Trials by Condition

Endometrial Cancer TrialsEssential Tremor TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY